Vivo Capital Discloses 23.86% Stake in InMed Pharmaceuticals Following Mentari Merger
INM has more than doubled off its 52-week low of $0.575.
Summary
Vivo Capital and its affiliates have reported a new 23.86% ownership stake in InMed Pharmaceuticals, a strategic investment linked to the recent merger with Mentari Therapeutics.
Key Events · Ownership and Investor Activity · INM
-
New Significant Ownership
Vivo Opportunity Fund Holdings, L.P. and its affiliates have disclosed a 23.86% beneficial ownership stake in InMed Pharmaceuticals Inc.
-
Merger-Related Investment
The stake was acquired in connection with the all-stock merger with Mentari Therapeutics, Inc., including participation in a pre-closing financing and open market purchases between May 19 and June 8, 2026.
-
Substantial Investment
The reported stake represents a significant investment, valued at over $1.1 million based on current share prices, in a company with a market capitalization of approximately $5 million.
Analysis · INM · Life Sciences
Vivo Opportunity Fund Holdings and its affiliates have disclosed a significant 23.86% beneficial ownership stake in InMed Pharmaceuticals. This substantial investment, valued at over $1.1 million, was acquired through a combination of pre-closing financing related to the Mentari Therapeutics merger and open market purchases. This filing provides crucial insight into the new ownership structure following the recently announced all-stock merger, indicating strong institutional backing for the combined entity.
At the time of this filing, INM was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.58 to $5.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.